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Predictive medicine seeks to ~redlcx suscept!bi I ~tv to d!seasas with I view to 
their preventijon ~nd ear~y diagnosis, as we! I as to ~mproved prognoS1$ and 
eventual treatmento Th® Commission ha~ proposed a new Commun~ty research 
programme In this f!®ici based on the use of new b~otachnologi@@p and especlally 
on human genome ana~ys!so The brogramme ,~ ®~peeted to run from 1989 to 1991 at 
a total cost o'if 30 mi I~ ion ECUo H Is rornposed Urnt Hi® CommunUy contribution· 
be 15 ml i 1·1on ECU 9 w~th matched funding from nat~onaij sources. 
FI f ty years ago the pr Inc! pad c~usa of mortd di Uy andl mor hd Hy was ! nfect lous 
disease but w~th the d~scovery of antibiotics, and improvements ~n hygiene and 
pest controij ~ H Is now a minor one !n lndustr!©I! h:edl courrtrh:is. Apart from the 
consequences of accident or ~arp muc~ ci!se~se today has~ genetic component 
which may be of gre~ter or lesser Importance. over the past few years a great 
deal has been ijearned about those diseases which are due to the lnherJtance of a 
single defective gene~ though In most cases we are ~ti ~i very far from a remedy, 
e.g. cystic fijbros~sp sffc~ffe eel I d!~easep duehanne museui~r dystrophy. 
However, when it come~ to t~a eommon disa~ses such~@ coronary artery disease, 
diabetes, cancerp auto-~mmune dis®asasp th® major psychosas ~nd other Important 
diseases of Western soc!etyp the position is f~r ~~ss e~ear. These conditions 
have a strong env~ronmentai component ~nci a~though genat~e factors are 
undoubtedly Involved, they do not fol low any eie~r-cut p~ttern of Inheritance. 
Put another wayp the d~sease resu~ts from the e~posure of genetically 
susceptlb~® !nd!vidua~s or popuiat~ons to environment~! causes; prevention wlll 
depend on reducl~g the !®veis 01 e~posur® either in popuiat~ons or» more 
probably9 ~n ~useept!b!e !nd!v!duaiso 
As It is most uni lkeiy th~t w® wi ii b® able to remova eompi~te~y the 
envlronmenta! risk 1actorsp It is important th~t we learn as much as possible 
about the ganet~caiiy ciatarmined pred!~po$lng factors an hence ijdentlfy high-
risk Individual~" Predict iv® Medicine se~ks to prot®et tndlvlduais from the 
kinds of I I ;nesse~ to wh!c~ they are gen®tic~I iy most vuin®rabi~o 
The human genom~ ,~ the compi®t® set of genetic m~t®riai {cieo~yrlbonucielc acid, 
or DNA) found in the hum~n cei~p and whijch embodies tha ijnsiruct~ons describing 
each human being. ~t Is now poss!bi® to anaiys®p or m~pp the genome Is such a 
way that one can "r~ad~ these Instructions and 9 ~n so do~ngv ~ocate the genes 
whlchp when aiteredv give rise to par~icu!sr d!saa~e~" Along the way It wlll be 
possible to make fundamental n®w d~scover!e~ ~n medic~~ bloiogy" 
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The approach to predictive medicine embodied In this programme wlll be that of 
human genome analysis, and wlll contain the follow·1ng elements: 
Improvement of the resolution of the human genetic map, I.e. creation of a 
map of the human genome, consisting of DNA markers, which would enable 
researchers to locate genes easily and quickly; 
the setting up of ordered 1 DNA llbralrles, I.e. of collections of ordered 
sets of DNA fragments which fully represent the DNA present In the entire 
genome, selected chromosomes or chromosomal fragments; 
the Improvement of advanced genetic technologies and, through a training 
programme, the spreading of these advanced technologies throughout the 
· Member States. 
The programme wl II establish networks of European laboratories already working 
In this fleld, coordinating research Into molecular genetics to achieve a better 
understanding of genetic disease and hence to Improve the prospects for 
diagnosis and therapy. 
The programme shall be Implemented through cost-shared or marginal cost 
contracts, support to centralized facilities and networks, training contracts, 
training grants, courses, consultatlons with na,ronal experts, organization of 
study-group meetings, participation In seminars and symposia, and publications. 
The Commission participation may range from about 50% In the case of cost-shared 
contracts and may reach 100%.ln other cases. 
Participants may be research Institutions, universities, Industrial enterprises 
or combinations of them, located In Member States or In certain third countries. 
Projects must be carried out by participants from more than one country, and 
Include at least one participant from one Member State. 
